AnderssonL.: Treatment of so-called essential haematuria with fibrinolytic inhibitor (epsilon-aminocaproic acid). Acta Chir. Scand., 124; 355 (1962).
2.
BoyceW. H., KingJ. S.jr., FieldenM.: Total nondialyzable solids (TNDS) in human urine. XIII. Immunological detection of a component peculiar to renal calculus matrix and to urine of calculus patient. J. Clin. Invest., 41; 1180 (1962).
3.
CharltonC. A. C.: Pathogenesis of urolithiasis: relation of urinary fibrinolytic activity to nondialyzable urinary solids. Surg. Forum, 17; 503 (1966).
4.
CharltonC. A. C.: Fibrinolysis and urolithiasis. Lancet, 1; 1199 (1967).
5.
CharltonC. A. C.: in: Renal stone research symposium. HodgkinsonA., NordinB. E. C. eds., pag. 191. Churchill, London1968.
6.
DrachG. W., KraljevichZ., RandolphA. D.: Effects of high molecular weight urinary macromolecules on crystallization of calcium oxalate dihydrate. J. Urol., 127; 805 (1982).
7.
HallsonP. C., RoseG. A.: Uromucoids and urinary stone formation. Lancet, 1; 1000 (1979).
HisazumiH., AnderssonL., LjungqvistA.: The effect of antifibrinolysis on renal stone formation. Urol. Res., 9; 67 (1981).
10.
KitamuraT., PakC. Y. C.: Tamm and Horsfall glycoprotein does not promote spontaneous precipitation and crystal growth of calcium oxalate in vitro. J. Urol., 127; 1024 (1982).
11.
TokiN., SumiH.: Urinary trypsin inhibitor and urokinase activities in renal diseases. Acta haemat., 67; 109 (1982).